Michael Feld, the Chief Revenue Officer of Becton Dickinson, executed a transaction involving the sale of 76 shares of the company's stock on October 26, 2026. This sale was made at a price of $198.13 per share, as reported in a recent filing.

This transaction is noteworthy as it is part of a pre-established Rule 10b5-1 plan, which allows executives to sell shares at predetermined times, thereby providing a layer of protection against accusations of insider trading. Following this sale, Feld retains ownership of 19,568 shares of Becton Dickinson.

Background

Becton Dickinson & Co, identified by CIK 0000010795, is a prominent player in the surgical and medical instruments and apparatus sector. The company is incorporated in New Jersey and has its fiscal year ending on September 30. Becton Dickinson is known for its innovative medical technologies and solutions.

What the Filing Says

"This reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 27, 2026."

Impact

This transaction may impact shareholders and potential investors as it reflects the ongoing management activity and decision-making within Becton Dickinson. Such transactions are closely monitored by stakeholders in the medical instruments industry, where transparency and compliance are critical.

What's Next

The filing does not say what happens next.